Sensitizing mutations in the epidermal growth factor receptor (EGFR) predict response to
EGFR tyrosine kinase inhibitors (TKIs) and both first-and second-generation TKIs are …

Tumours with sensitizing mutations in the EGFR gene constitute a distinct molecular
subgroup of non-small-cell lung cancers (NSCLCS) that benefit from precision medicine …

First generation or second generation EGFR tyrosine kinase inhibitors are currently the
standard of care for the first-line management of non-small cell lung cancer (NSCLC) …

Over the past 2 decades, rapid advances in molecular profiling and the development of
targeted therapies have dramatically improved the clinical course of advanced non-small …

The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene
and the development of EGFR tyrosine kinase inhibitors (TKIs) have led to a paradigm shift …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) represent the
standard of care for advanced non-small cell lung cancer (NSCLC) patients whose tumours …

First-and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung …

Introduction: despite initial dramatic efficacy of EGFR tyrosine kinase inhibitors (TKIs) in
EGFR-mutant lung cancer patients, emergence of acquired resistance is almost inevitable …

The discovery that mutations in the EGFR gene are detected in up to 50% of lung
adenocarcinoma patients, along with the development of highly efficacious epidermal …

The identification of epidermal growth factor receptor (EGFR) mutations represented a
fundamental step forward in the treatment of advanced non-small cell lung cancer (NSCLC) …